Woodmont Investment Counsel LLC Raises Position in Pfizer Inc. (NYSE:PFE)

Woodmont Investment Counsel LLC grew its position in Pfizer Inc. (NYSE:PFE) by 12.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 120,054 shares of the biopharmaceutical company’s stock after acquiring an additional 12,883 shares during the period. Woodmont Investment Counsel LLC’s holdings in Pfizer were worth $3,332,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Clifford Swan Investment Counsel LLC boosted its holdings in shares of Pfizer by 4.7% in the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after acquiring an additional 18,611 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the period. LifePlan Financial LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $255,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $16,166,000. Finally, KLCM Advisors Inc. lifted its stake in shares of Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after purchasing an additional 74,487 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.4 %

Pfizer stock traded down $0.39 during trading on Tuesday, reaching $27.83. The company had a trading volume of 12,856,852 shares, compared to its average volume of 40,569,621. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80. The stock’s 50 day moving average price is $27.90 and its two-hundred day moving average price is $27.69. The firm has a market capitalization of $157.70 billion, a price-to-earnings ratio of -466.59, a PEG ratio of 1.10 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the previous year, the firm earned $1.23 earnings per share. Pfizer’s revenue was down 19.5% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analyst Ratings Changes

Several analysts recently commented on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley lifted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, June 26th. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $35.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.